68-29-05

7/50/21 (02.04)

TO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/698,983 10/31/2003 Filing Date TRANSMITTAL **FORM** First Named Inventor **Howard Sands** (to be used for all correspondence after initial filing) Art Unit 1614 **Examiner Name** Not yet assigned Total Number of Pages in This Submission 9 Attorney Docket Number 12636-304.201 ENCLOSURES (Check all that apply) After Allowance communication to Fee Transmittal Form Drawing(s) Technology Center (TC) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) Extension of Time Request Terminal Disclaimer (please identify below): return receipt postcard Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Shirley Chen, Reg. No. 44,608, WILSON SONSINI GOODRICH & ROSATI Individual name Signature 8-24-05 Date

> Express Mail Date: August 25, 2005 Express Mail Label No.: EV518897128US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT Attorney Docket No. 12636-304.201

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Howard SANDS, et al.

Serial Number: 10/698,983

Filing Date: October 31, 2003

Title: PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT Group Art Unit: 1614

Examiner: Not yet assigned

**CONFIRMATION NO: 8849** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08A. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

⊠ becaus		TR §1.97(b). This Information Disclosure Statement should be considered by the Office
		(1) It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d); OR
		(2) It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application; OR
	$\boxtimes$	(3) It is being filed before the mailing date of the first Office Action on the merits; OR
	. 🗆	(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.
	specifi office closes	R §1.97(c). Although this Information Disclosure Statement is being filed after the period ed in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise prosecution on the merits, this Information Disclosure Statement should be considered because companied by one of:
		a certification as specified in §1.97(e) provided concurrently herewith; OR
		a fee of \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.
	date o	$R \ \S 1.97(d)$ . Although this Information Disclosure Statement is being filed after the mailing of the earlier of (1) a final office action under $\S 1.113$ or (2) a notice of allowance under $\S 1.311$ , reing filed before payment of the issue fee and should be considered because it is accompanied
•	A.	a certification as specified in §1.97(e); and
	B.	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.
		FR §1.97(e). A certification signed by an Attorney of Record is provided herewith as required 37 CFR §§1.97(b) and (c).
$\boxtimes$	37 CF	$R \ \S 1.98(a)(2)$ . The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed herewith.
	$\boxtimes$	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed.
		AND/OR
	$\boxtimes$	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2).

		AND/OR	
		Copies of pending unpublished U.S. 37 CFR §1.98(a)(2)(iii).	patent applications are enclosed in accordance with
	37 CF.		sure Statement includes non-English patents and/or
•		publication or other information provided DE 1922702 was published in German. Sufficient to convey the scope of its discount to convey the scope of its WO 03/040363 was published in Japanear sufficient to convey the scope of its WO 03/046190 was published in Germa are sufficient to convey the scope of its Should the Examiner believe that a convey that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should the Examiner believe that a convey the scope of its should be sho	The English language abstract and the drawings are closure.  370939 and JP 2003310293 were published in its are sufficient to convey the scope of their ese. The English language abstract and the drawings disclosure.  an. The English language abstract and the drawings disclosure.  complete translation of any of the above mentioned their disclosure, Applicant(s) will endeavor to provide
		reference(s) is provided herewith. CS 269077 was published in Czech. T sufficient to convey the scope of its disc	n. The English language translation and the drawings
			n corresponding patent application(s), submitted in attached certification under 37 CFR §1.97(e)(1).
$\boxtimes$	\$0.00 a		by authorized to charge the above-referenced fees of any overpayment associated with this communication (636-304.201).
			Respectfully submitted,
			WILSON SONSINI GOODRICH & ROSATI
Dated:		8-24-05	By: Shirley Chen, Reg. No. 44,608

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971 PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Application Number 10/698,983 Substitute for form 1449/PTO 10/31/2003 Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor **Howard Sands** (Use as many sheets as necessary) Art Unit 1614 **Examiner Name** Not yet assigned Sheet of 5 Attorney Docket Number 12636-304.201

		U.S. PA	TENT DOC	UMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2001/0012835 A1	04/14/1997	Fine, et al.	· ·
		US-2002/0114809 A1	02/21/2001	Rubinfeld, et al.	
		US-2002/0136709 A1	07/31/2001	Zahner	
		US-2003/0013099 A1	03/19/2001	Lasek, et al.	<del></del>
		US-2003/0039689 A1	04/26/2002	Chen, et al.	•
		US-2003/0045497 A1	07/26/2002	Widegren, et al.	
		US-2003/0108588 A1	09/17/2002	Chen, et al.	
		US-2003/0147813 A1	02/07/2002	Lyons	
		US-2003/0165864 A1	01/16/2002	Lasek, et al.	
		US-2003/0171303 A1	06/11/2002	Gallop, et al.	
		US-2003/0229047 A1	06/05/2002	Joshi-Hangal, et al.	
		US-4,690,918	09/01/1987	Beppu, et al.	
		US-5,736,531	12/30/1993	Von Borstel, et al.	
		US-5,856,090	09/09/1994	Epstein	
		US-5,856,094	06/30/1995	Sidransky, et al.	
		US-5,968,914	10/28/1987	Von Borstel, et al.	
		US-6,136,791	12/23/1996	Nyce	
		US-6,255,293 B1	07/24/1998	Kimchi	

Examiner	Date	
Signature	Consider	lered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	2 2			Con	nplete if Known
Substitute for	or form 144	9/PTO		Application Number	10/698,983
INFORM	<b>IATION</b>	DISC	LOSURE	Filing Date	10/31/2003
			LICANT	First Named Inventor	Howard Sands
(Use as	s many shee	ts as ne	cessary)	Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	2	of	5	Attorney Docket Number	12636-304.201

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T'
		CS 269077	12/22/1963	Ceskoslovenska		
				akademie ved, (Prag)	ļ ,	↓_
•		DE 1922702	05/03/1969	Ceskoslovenska akademie ved, (Prag)		
		DE 2105468	02/05/1971	Ceskoslovenska akademie ved, (Prag)		
	-	EP 286958	04/06/1988	Merck Pg		Г
		JP 05219974	02/13/1992	Mitsui Petrochem Ind Ltd	*	
	-	JP 2002223753	01/30/2001	Hitachi		1
		JP 2002370939	06/12/2001	Taisho Pharmaceutical Co. Ltd.	•	
at at		JP 2003310293	04/26/2002	Mitsui Chemical Inc.		T
		PCT/US04/22367 International Search Report	07/20/2005	SuperGen, Inc.		T
		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		H
		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		t
		WO 94/27632	06/01/1993	Nycomed Pharma A/S		T
		WO 96/11280	10/07/1994	East Carolina University		
		WO 96/36693	05/19/1995	Phytera, Inc.		Τ
		WO 96/39035	06/06/1995	Case Western Reserve Unniversity		
		WO 96/40165	06/07/1995	Pro-Neuron, Inc.		T
Ó		WO 98/14619	10/03/1996	Incyte Pharmaceuticals, Inc.		
		WO 98/16186	10/16/1996	ICN Pharmaceuticals		T
		WO 98/29108	12/30/1996	Andrew, P. Feinberg		T
·· ,		WO 98/54318	05/28/1997	Marie Curie Research Institute		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Trainstation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Index the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Con	plete if Known
Substitute fo	or form 1449	/PTO		Application Number	10/698,983
INFORM	IATION I	DISC	LOSURE	Filing Date	10/31/2003
			LICANT	First Named Inventor	Howard Sands
(Use as	many sheets	s as nec	cessary)	Art Unit	1614
			•	Examiner Name	Not yet assigned
Sheet	3	of	5	Attorney Docket Number	12636-304.201

Examiner	Cite	Foreign Patent Document	PATENT DO Publication Date	Name of Patentee or	Pages, Columns, Lines,	Τ
Initials*	No.1	Country Code' - Number' - Kind Code' (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т
		WO 00/05419	07/24/1998	Yeda Research and		Γ
				Development		
				Company Ltd.		
		WO 00/23112	10/19/1998	Methylgene, Inc.		
		WO 00/40269	01/05/1999	Clarence Lee		Γ
		WO 00/54574	03/18/1999	The University of		Γ
				Chicago		
		WO 00/62075	04/13/1999	Rutgers, The State		
				University of New		
				Jersey		┸
i		WO 01/21215 A1	09/22/1999	Ortho-McNeil		
				Pharmaceutical, Inc.		1
		WO 01/69262 A1	03/15/2000	University of		1
				Massachusetts		╀
		WO 01/79164 A2	03/21/2000	Atherogenics, Inc.		$\perp$
		WO 02/18592 A1	09/01/2000	Bionomics Limited		
		WO 02/21140 A1	09/08/2000	Metabolic Engineering		
				Laboratories Co., Ltd.		┸
		WO 02/051980 A2	12/12/2000	Nucleus Remodeling,	•	
				Inc.		L
		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		L
		WO 02/069903 A3	03/06/2001	Biocryst		
				Pharmaceuticals, Inc.		$\perp$
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		
		WO 02/083705 A1	04/13/2001	The Johns Hopkins		ſ
				University School of		
				Medicine	•	L
		WO 02/085400 A1	04/24/2001	Supergen, Inc.		
		WO 02/087586 A1	04/26/2001	Control Delivery		Γ
				Systems, Inc.		
		WO 03/006950 A2	07/12/2001	Geron Corporation		Γ

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Con	nplete if Known
Substitute f	or form 144	9/PTO		Application Number	10/698,983
INFORM	IATION	DISC	LOSURE	Filing Date	10/31/2003
			LICANT	First Named Inventor	Howard Sands
(Use as	s many shee	ts as nec	cessary)	Art Unit	1614
_				Examiner Name	Not yet assigned
Sheet	4	of	5	Attorney Docket Number	12636-304.201

xaminer Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		WO 03/012112 A1	07/27/2001	Geneinvent BBL AB		П
		WO 03/012085 A1	07/30/2001	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.		
		WO 03/011209 A2	07/31/2001	Yeda Research and Development Co. Ltd.		
		WO 03/026574 A2	09/24/2001	AU, Jessie, LS.		Γ
		WO 03/031932 A2	10/05/2001	Case Western Reverse Univresity		
		WO 03/040363 A1	11/08/2001	Japan Science and Technology Corporation		
		WO 03/043631 A2	11/23/2001	F. Hoffman-LA Roche AG		
		WO 03/045427 A2	11/29/2001	Dandrit Biotech A/S		T
		WO 03/046190 A1	11/30/2001	Medigene Aktiengesellschaft		
		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		Т
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 03/086374 A1	04/05/2002	University of Utah Research Foundation		
		WO 2003/087774 A3	04/12/2002	Gurators of the University of Missouri		
		WO 03/104427 A2	06/05/2002	Case Western Reserve University		
		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		Γ

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO 10/698,983 **Application Number** INFORMATION DISCLOSURE 10/31/2003 Filing Date STATEMENT BY APPLICANT First Named Inventor **Howard Sands** (Use as many sheets as necessary) Art Unit 1614 **Examiner Name** Not yet assigned 12636-304.201 Attorney Docket Number Sheet 5 of 5

T²	NON PATENT LITERATURE DOCUMENTS
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	VON HOFF, et al., "5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia," Annals of Internal Medicine (1976) 85(2), pages 237-245
	·
	·
	xaminer Date

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.